psoriasis
Conditions
Interventions
Intervention group:PSORI-CMO1 granules+balneotherapy + coal tar
Control group:PSORI-CMO1 placebo granules+balneotherapy + coal tar
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with psoriasis vulgaris; 2. Male or female patient between 18 to 65 years old; 3. PASI more than 10 and less than 30, and BSA more than 10 and less than 30; 4. Can read and understand by themselves; 5. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Psoriatic lesions can only be seen on face, scalp, nails, balanus, mucus and palmarplantar areas; 2. Pregnant, lactating, or those who plan to become pregnant in a year; 3. SAS more than 50 or SDS more than 53, or with other psychiatric disorders; 4. With history of primary cardiovascular, respiratory, digestive, urinary, endocrinologic and hematologic diseases, which cannot be controlled through ordinary treatments. Those who with malignant diseases, infections, electrolyte imbalance, acid-base disturbance, acute infectious disease, wound, acute arthritis, malnutrition. Patients with clinical test results listed below: AST or ALT 3 times more than normal upper limit; Creatinine 1.5 times more than normal upper limit; Hemoglobin elevates 20g/L more than normal upper limit; Platelet count less than 75.0*10^9/L; White blood cell less than 3.0*10^9/L; Or any other abnormal laboratory test results, assessed by investigators, that are not suitable for this clinical study; 5. Allergic to any medicine or ingredients used in this study; 6. Participating other clinical trials or participated within 1 month; 7. Topical treatments with corticosteroids or Retinoic acid within 2 weeks; systemic therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12 weeks; 8. Psoriatic arthritis, and erythroderma tendency; 9. Patients need systemic treatment with western medicine.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| improvement rate of PASI;body surface area;Physician’s Global Assessment;visual analogue scale;self-administered psoriasis area and severity index;Dermatology Life Quality Index;Skindex16; | — |
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity Index score;Relapse rate in treatment period / follow-up period; | — |
Countries
China
Contacts
Public ContactChuanjian Lu
Outcome results
None listed